FrancophonIA/ELRC3.0 huggingface dataset:
English: In female mice, an increased incidence of mammary gland adenocarcinoma and adeno-squamous carcinoma, and pars distalis adenoma of the pituitary gland, was observed at similar or even lower clinically relevant exposures: these prolactin-mediated endocrine tumours were also observed in rodents with other antipsychotics and their clinical relevance is unknown.
Croatian: U ženki miša opažena je povećana incidencija adenokarcinoma i adenoskvamoznog karcinoma mliječne žlijezde te adenoma prednjeg režnja hipofize pri sličnim ili čak nižim klinički značajnim izloženostima: ovi prolaktinom posredovani endokrini tumori također su bili opaženi u štakora kod primjene drugih antipsihotika i njihova klinička važnost nije poznata.
English: Do not use this medicine after the expiry date, which is stated on the blister and on the outer carton after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru i kutiji iza oznake „EXP“.
English: Overall in the brexpiprazole clinical development program for schizophrenia, one death due to suicide, considered not drug related by the investigator, occurred.
Croatian: U programu kliničkog razvoja brekspiprazola za liječenje shizofrenije, ukupno se dogodio jedan smrtni slučaj zbog samoubojstva koji, po mišljenju ispitivača, nije bio povezan s lijekom.
English: • or had dizziness on standing up due to a drop in your blood pressure, which may cause fainting.
Croatian: • ili ste imali omaglicu pri ustajanju zbog pada krvnog tlaka, što može uzrokovati nesvjesticu.
English: If brexpiprazole is administered concomitantly with medicinal products known to increase creatine phosphokinase (CPK) the possible additive effect with CPK increase induced by brexpiprazole should be considered.
Croatian: Ako se brekspiprazol primjenjuje istodobno s lijekovima za koje je utvrđeno da povećavaju kreatin fosfokinazu, potrebno je uzeti u obzir mogući aditivni učinak s povećanjem kreatin fosfokinaze izazvanim brekspiprazolom.
English: In the flexible-dose trial 4, at week 6, subjects in the brexpiprazole treatment group had numerically greater improvements on PANSS total score than the subjects in the placebo group, although, the difference at week 6 did not reach statistical significance for the primary efficacy analysis (p = 0.0560; see table 2).
Croatian: U ispitivanju fleksibilne doze, ispitivanju 4, ispitanici u skupini liječenoj brekspiprazolom imali su u 6. tjednu brojčano veće poboljšanje ukupnog rezultata na ljestvici PANSS nego ispitanici u skupini koja je primala placebo, iako razlika u 6. tjednu nije dosegnula statističku značajnost u analizi primarne mjere djelotvornosti (p = 0,0560, vidjeti tablicu 2).
English: Brexpiprazole did not show any genotoxic potential in both in vitro and in vivo studies using clinically relevant exposures.
Croatian: Brekspiprazol nije pokazao genotoksični potencijal niti u in vitro ni u in vivo ispitivanjima pri klinički značajnoj izloženosti.
English: The efficacy and safety of brexpiprazole in the treatment of adults with schizophrenia was studied in two multi-national and one regional (Japan), 6-week, randomised, double-blind, placebo-controlled, fixed-dose clinical trials (trials 1 to 3), a multi-national, 6-week, randomised, double-blind, placebo-controlled, active reference (quetiapine), flexible-dose clinical trial (trial 4), and, one multi-national, placebo-controlled, 52-week maintenance trial (trial 5).
Croatian: Klinička djelotvornost i sigurnost Djelotvornost i sigurnost brekspiprazola u liječenju odraslih sa shizofrenijom bila je ispitana u dva multinacionalna i jednom regionalnom (Japan) randomiziranom, dvostruko slijepom, placebom kontroliranom kliničkom ispitivanju fiksne doze u trajanju od 6 tjedana (ispitivanja 1 do 3), jednom multinacionalnom randomiziranom, dvostruko slijepom, placebom i referentnim lijekom (kvetiapinom) kontroliranom kliničkom ispitivanju fleksibilne doze u trajanju od 6 tjedana (ispitivanje 4) te jednom multinacionalnom, placebom kontroliranom ispitivanju terapije održavanja u trajanju od 52 tjedna (ispitivanje 5).
English: Brexpiprazole is highly protein bound in plasma (greater than 99 %) to serum albumin and α1-acid glycoprotein, and its protein binding is not affected by renal or hepatic impairment.
Croatian: Brekspiprazol se u visokom postotku veže za proteine plazme (više od 99 %) serumski albumin i α1-kiseli glikoprotein i oštećenje bubrega ili jetre ne utječe na njegovo vezanje za proteine.
English: Cardiovascular toxicity
Croatian: Kardiovaskularna toksičnost
English: Subgroup analyses from this trial suggested that the QTc prolongation was larger in female subjects than in males (see section 5.1).
Croatian: Analiza podskupina u ovom ispitivanju pokazala je da je produljenje QTc-intervala bilo veće u ispitanica nego u muških ispitanika (vidjeti dio 5.1).
English: A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with brexpiprazole (see section 4.4).
Croatian: Zabilježen je potencijalno smrtonosan kompleks simptoma pod nazivom maligni neuroleptični sindrom (MNS) povezan s brekspiprazolom (vidjeti dio 4.4).
English: Brexpiprazole (2 mg/day)* 180 95.85 Brexpiprazole (4 mg/day)* 178 94.70
Croatian: (2 mg na dan)* 180 95,85 (4 mg na dan)* 178 94,70
English: In rabbit, vertebral malformations were seen in 3 foetuses from 2 litters at maternally toxic brexpiprazole oral doses corresponding to exposure approximately 16.5-fold the clinical exposure at MRHD.
Croatian: U kunića su opažene malformacije kralježnice u 3 fetusa iz 2 okota pri peroralnim dozama brekspiprazola toksičnima za majku koje su odgovarale izloženosti približno 16,5 puta većoj od kliničke izloženosti pri MRHD.
English: Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) Orthostatic hypotension
Croatian: (uključujući plućnu emboliju i duboku vensku trombozu) ortostatska hipotenzija
English: Caution should be exercised when brexpiprazole is prescribed in patients with known cardiovascular disease, family history of QT prolongation, electrolyte imbalance or in concomitant use with other medicinal products thought to prolong the QT interval (see sections 4.8 and 5.1).
Croatian: Potreban je oprez kad se brekspiprazol propisuje bolesnicima s utvrđenom kardiovaskularnom bolešću, produljenjem QT-intervala u obiteljskoj anamnezi, poremećajem ravnoteže elektrolita ili onima koji istodobno uzimaju druge lijekove za koje se smatra da produljuju QT-interval (vidjeti dijelove 4.8 i 5.1).
English: Antipsychotics including brexpiprazole have been associated with metabolic changes, including weight gain and dyslipidaemia.
Croatian: Antipsihotici, pa i brekspiprazol, povezani su s metaboličkim promjenama, uključujući povećanje tjelesne težine i dislipidemiju.
English: • are having any thoughts or feelings about hurting yourself or to commit suicide.
Croatian: • razmišljate o samoozljeđivanju ili samoubojstvu ili osjećate da biste si mogli nauditi ili počiniti samoubojstvo.
English: Neonates exposed to antipsychotics, including brexpiprazole, during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.
Croatian: U novorođenčadi izložene antipsihoticima, uključujući brekspiprazol, tijekom trećeg tromjesečja trudnoće postoji rizik od nuspojava uključujući ekstrapiramidne simptome i/ili simptome ustezanja koji mogu biti različite jačine i trajanja nakon porođaja.
English: It should be noted that in vivo preclinical studies have shown that at clinically relevant plasma exposures of brexpiprazole, DM-3411 brain exposures were below the detection limit.
Croatian: Potrebno je naglasiti da su neklinička ispitivanja in vivo pokazala da je izloženost mozga metabolitu DM-3411 pri klinički značajnoj izloženosti brekspiprazolu u plazmi bila ispod granice mjerljivosti.
English: Population pharmacokinetic evaluation shows that CYP2D6 poor metabolisers have 47 % higher exposure to brexpiprazole compared to extensive metabolisers (see section 4.2).
Croatian: Genotip CYP2D6 Populacijska farmakokinetička procjena pokazuje da spori metabolizatori CYP2D6 imaju 47 % veću izloženost brekspiprazolu u usporedbi s brzim metabolizatorima (vidjeti dio 4.2).
English: • during blood tests your doctor may find higher amounts of creatine kinase (also called creatine phosphokinase) in your blood (enzyme important for muscle function).
Croatian: • na krvnim pretragama, liječnik Vam može pronaći veće količine kreatin kinaze (koja se još naziva kreatin fosfokinaza) u krvi (enzim važan za rad mišića).
English: These improvements were maintained during the 52-week double-blind maintenance phase in patients on brexpiprazole whereas patients randomised to placebo showed deterioration in PANSS, CGI-S and CGI-I, and GAF scores [ANCOVA LOCF]).
Croatian: Ta su poboljšanja održana tijekom dvostruko slijepe faze održavanja u trajanju od 52 tjedna u bolesnika liječenih brekspiprazolom, dok se u bolesnika randomiziranih da primaju placebo pokazalo pogoršanje rezultata na ljestvici PANSS, CGI-S i CGI-I te GAF-u [ANCOVA LOCF].
English: • akathisia (an uncomfortable feeling of inner restlessness and a compelling need to move constantly),
Croatian: • povećanje tjelesne težine • akatizija (neugodan osjećaj unutarnjeg nemira i nesavladiva potreba za neprekidnim kretanjem)
English: What you need to know before you take RXULTI Do not take RXULTI
Croatian: Što morate znati prije nego počnete uzimati RXULTI
English: Orthostatic hypotension and syncope
Croatian: Ortostatska hipotenzija i sinkopa
English: Table 3: Key secondary efficacy results for 6-week trials in schizophrenia Trial
Croatian: Tablica 3: Ključni rezultati sekundarnih mjera djelotvornosti u 6-tjednim ispitivanjima kod shizofrenije
English: Brexpiprazole is absorbed after administration of the tablet, with peak plasma concentrations occurring within 4.0 hours after single dose administrations; the absolute oral bioavailability of the tablet formulation is 95.1 %.
Croatian: Brekspiprazol se apsorbira nakon primjene tablete, a vršne koncentracije u plazmi postiže unutar 4,0 sata nakon primjene jedne doze; apsolutna peroralna bioraspoloživost formulacije u obliku tablete je 95,1 %.
English: The effects of brexpiprazole on the QT interval were evaluated in patients with schizophrenia or schizoaffective disorder.
Croatian: Učinci brekspiprazola na QT-interval bili su procijenjeni u bolesnika sa shizofenijom ili shizoafektivnim poremećajem.
English: Additional signs may include increased creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
Croatian: Dodatni znakovi mogu uključivati povišene vrijednost kreatin fosfokinaze, mioglobinuriju (rabdomiolizu) i akutno zatajenje bubrega.
English: In trial 5, a long-term trial designed to assess the maintenance of effect of brexpiprazole by assessing the delay in time to impending relapse of schizophrenia, patients with schizophrenia, who responded to treatment with brexpiprazole 1 mg/day to 4 mg/day, were stabilised over 12 weeks to 36 weeks, and then randomised in a double-blind manner to either continue treatment with the stabilisation dose of brexpiprazole (n = 96) or to receive placebo (n = 104) for 52 weeks or until relapse occurred.
Croatian: U ispitivanju 5, dugotrajnom ispitivanju provedenom radi procjene održanja učinka brekspiprazola procjenom produljenja razdoblja do prijetećeg relapsa shizofrenije, bolesnici sa shizofrenijom, koji su odgovorili na liječenje brekspiprazolom u dozi od 1 mg na dan do 4 mg na dan, bili su stabilizirani tijekom 12 tjedana do 36 tjedana te potom randomizirani na dvostruko slijep način da nastave liječenje stabilizirajućom dozom brekspiprazola (n = 96) ili da primaju placebo (n = 104) tijekom 52 tjedna ili do pojave relapsa.
English: Lactose monohydrate, maize starch, microcrystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, magnesium stearate, purified water.
Croatian: Laktoza hidrat, kukuruzni škrob, mikrokristalična celuloza, nisko supstituirana hidroksipropilceluloza, hidroksipropilceluloza, magnezijev stearat, pročićena voda.
English: Studies in animals have shown decreased female fertility (see section 5.3).
Croatian: Ispitivanja na životinjama pokazala su smanjenu plodnost ženki (vidjeti dio 5.3).
English: Neuroleptic malignant syndrome
Croatian: Maligni neuroleptični sindrom
English: Potential for other medicinal products to affect brexpiprazole
Croatian: Mogućnost utjecaja drugih lijekova na brekspiprazol
English: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotics.
Croatian: Antipsihoticima se pripisuje narušavanje sposobnosti tijela da snizi unutarnju tjelesnu temperaturu.
English: CYP3A4 inducers exert their effect in a time-dependent manner, and may take at least 2 weeks to reach maximal effect after introduction.
Croatian: Učinak induktora CYP3A4 ovisan je o vremenu te nakon njihova uvođenja može biti potrebno najmanje 2 tjedna da bi postigli maksimalni učinak.
English: Appropriate care is advised when prescribing brexpiprazole for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medicinal products with anticholinergic activity, or being subject to dehydration.
Croatian: Savjetuje se odgovarajući oprez kad se brekspiprazol propisuje bolesnicima u kojih će nastati stanja koja mogu pridonijeti povišenju unutarnje tjelesne temperature, npr. naporna tjelovježba, izloženost velikoj vrućini, istodobno uzimanje lijekova s antikolinergičkim djelovanjem ili podložnost dehidraciji.
English: Patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and brexpiprazole should be discontinued at the first sign of decline in WBC, in the absence of other causative factors.
Croatian: U bolesnika s već niskim brojem bijelih krvnih stanica (leukocita) i leukopenijom/neutropenijom izazvanom lijekovima u povijesti bolesti treba često provjeravati kompletnu krvnu sliku (KKS) tijekom prvih nekoliko mjeseci terapije i primjenu brekspiprazola treba prekinuti na prvi znak sniženja broja leukocita u odsutnosti drugih uzročnih čimbenika.
English: The mean change in body weight overall for the brexpiprazole group in the long term, open label trial was 2.1 kg at week 52.
Croatian: Srednja vrijednost promjene tjelesne težine sveukupno u skupini liječenoj brekspiprazolom u dugotrajnom otvorenom ispitivanju iznosila je 2,1 kg u 52. tjednu.
English: An increased frequency of weight gain has been observed with increased duration of brexpiprazole treatment (see section 4.8).
Croatian: Opažena je povećana učestalost povećanja tjelesne težine s duljim trajanjem liječenja brekspiprazolom (vidjeti dio 4.8).
English: Effects on QT
Croatian: Učinci na QT-interval
English: Due to the testing hierarchy the greater improvement shown for both 2 mg/day and 4 mg/day on the CGI-S can only be considered supportive for trials 2, 3 and 4 (see table 3).
Croatian: Zbog hijerarhije testova, može se smatrati da veće poboljšanje u CGI-S i pri dozi od 2 mg na dan i pri dozi od 4 mg na dan samo potkrepljuje ispitivanja 2, 3 i 4 (vidjeti tablicu 3).
English: RXULTI film-coated tablets contain lactose.
Croatian: RXULTI filmom obložene tablete sadrže laktozu.
English: The categorisation of blood prolactin increased is based on Potentially Clinically Relevant (PCR) criteria of > 1 × upper limit of normal (ULN).
Croatian: Clinically Relevant, PCR) kriterijima od > 1 × gornja granica normale (GGN).
English: In case of adverse reactions despite dose adjustments of RXULTI, the necessity of concomitant use of RXULTI and CYP2D6 or CYP3A4 inhibitor should be reassessed.
Croatian: U slučaju nuspojava unatoč prilagodbama doze lijeka RXULTI, potrebno je ponovno procijeniti potrebu za istodobnom primjenom lijeka RXULTI i inhibitora CYP2D6 ili CYP3A4.
English: • combination of fever, sweating, muscle stiffness, and drowsiness or sleepiness.
Croatian: • kombinaciju vrućice, znojenja, ukočenosti mišića i omamljenosti ili pospanosti.
English: Tablet coat: Hypromellose, talc, titanium dioxide.
Croatian: Hipromeloza, talk, titanijev dioksid.
English: Higher frequencies of prolactin increased (1.5 % versus 0.60 %) were observed in females compared to males in short-term trials.
Croatian: Opažena učestalost povišenog prolaktina bila je veća u žena nego u muškaraca (1,5 % naspram 0,60 %) u kratkotrajnim ispitivanjima.
English: H. Lundbeck A/S Tel: +45 36301311
Croatian: Lundbeck A/S Tel: +45 36301311
English: Potential for brexpiprazole to affect other medicinal products
Croatian: Mogućnost utjecaja brekspiprazola na druge lijekove
English: • dizziness on standing up due to a drop in your blood pressure, which may cause fainting,
Croatian: • omaglica pri ustajanju zbog pada krvnog tlaka, što može uzrokovati nesvjesticu
English: At steady-state, DM-3411 represents 23.1 % to 47.7 % of brexpiprazole exposure (AUC) in plasma.
Croatian: U stanju dinamičke ravnoteže, DM-3411 predstavlja 23,1 % do 47,7 % izloženosti brekspiprazolu
English: Keep this medicine out of the sight and reach of children.
Croatian: Kako čuvati RXULTI Lijek čuvajte izvan pogleda i dohvata djece.
English: In short-term, controlled trials, Treatment Emergent Adverse Events (TEAEs) related to suicidality were reported for 8 subjects (0.5 %, 2 serious events, 1 leading to discontinuation) in the all brexpiprazole treatment group and 3 subjects (0.4 %, none serious) in the placebo group.
Croatian: Treatment Emergent Adverse Events, TEAEs) povezani sa suicidalnošću zabilježeni su u 8 ispitanika (0,5 %, 2 ozbiljna događaja, 1 koji je doveo do prekida uzimanja lijeka) u svim skupinama liječenima brekspiprazolom i 3 ispitanika (0,4 %, nijedan ozbiljan) u skupini koja je primala placebo.
English: The pharmacology of brexpiprazole is believed to be mediated by a modulatory activity at the serotonin and dopamine systems that combines partial agonist activity at serotonergic 5-HT1A and at dopaminergic D2 receptors with antagonist activity at serotonergic 5-HT2A receptors, with similar high affinities at all of these receptors
Croatian: Smatra se da je farmakologija brekspiprazola posredovana modulacijskim djelovanjem na serotoninski i dopaminski sustav, pri čemu se djelomično agonističko djelovanje na serotoninergičke receptore 5-HT1A i dopaminergičke receptore D2 kombinira s antagonističkim djelovanjem na serotoninergičke receptore 5-HT2A, uz slično jak afinitet za sve ove receptore (Ki: 0,1 nM do 0,5 nM).
English: There are no or limited amount of data from the use of brexpiprazole in pregnant women.
Croatian: Nema podataka ili su podaci o primjeni brekspiprazola u trudnica ograničeni.
English: RXULTI 0.25 mg, 0.5 mg, 2 mg, 3 mg and 4 mg film-coated tablets 28 film-coated tablets in Aluminium/PVC blisters.
Croatian: RXULTI 0,25 mg, 0,5 mg, 2 mg, 3 mg i 4 mg filmom obložene tablete 28 filmom obloženih tableta u aluminij/PVC blisterima.
English: Given the primary Central Nervous System (CNS) effects of brexpiprazole, caution should be used when brexpiprazole is taken in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).
Croatian: S obzirom na to da brekspiprazol primarno djeluje na središnji živčani sustav (SŽS), potreban je oprez kad se brekspiprazol uzima u kombinaciji s alkoholom ili drugim lijekovima koji djeluju na SŽS a imaju podudarne nuspojave poput sedacije (vidjeti dio 4.8).
English: Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia.
Croatian: Mogući čimbenici rizika za leukopeniju/neutropeniju uključuju već prisutan nizak broj bijelih krvnih stanica i leukopeniju/neutropeniju izazvanu lijekovima u povijesti bolesti.
English: If you have kidney problems, your doctor may adjust your dose of this medicine.
Croatian: Ako imate probleme s bubrezima, liječnik Vam može prilagoditi dozu ovog lijeka.
English: In placebo-controlled trials with some antipsychotics in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects.
Croatian: U placebom kontroliranim ispitivanjima nekih antipsihotika u starijih bolesnika s demencijom, incidencija cerebrovaskularnih nuspojava (cerebrovaskularnih incidenata i tranzitornih ishemijskih ataka), uključujući smrtne slučajeve, bila je viša nego u ispitanika koji su primali placebo.
English: The incidences of the ADRs associated with brexpiprazole therapy are tabulated below.
Croatian: Incidencije nuspojava povezanih s terapijom brekspiprazolom prikazane su u tablici niže.
English: Based on results of interaction studies, dose adjustment of brexpiprazole to half the dose is recommended when administered concomitantly with strong CYP3A4 inhibitors (itraconazole, ketoconazole, ritonavir, and clarithromycin).
Croatian: Na temelju rezultata ispitivanja interakcija preporučuje se prilagodba doze brekspiprazola na pola doze kad se primjenjuje istodobno s jakim inhibitorima CYP3A4 (itrakonazolom, ketokonazolom, ritonavirom i klaritromicinom).
English: Weight gain and dyslipidaemia
Croatian: Povećanje tjelesne težine i dislipidemija
English: Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia).
Croatian: ukočenost mišića, promijenjen mentalni status i znakovi autonomne nestabilnosti (nepravilan rad srca ili krvni tlak, tahikardija, dijaforeza i poremećaj srčanog ritma).
English: The pharmacokinetic of brexpiprazole is dose proportional and time-invariant after single-dose (0.2 mg to 8 mg) and multiple-dose (0.5 mg to 4 mg) using once-daily administration.
Croatian: Farmakokinetika brekspiprazola proporcionalna je dozi i ne mijenja se tijekom vremena nakon primjene jedne doze (od 0,2 mg do 8 mg) ili višestrukih doza (od 0,5 mg do 4 mg) jedanput dnevno.
English: If brexpiprazole is used concomitantly with strong CYP3A4 inducers (e.g. rifampicin), in a patient stabilised on brexpiprazole it is necessary to titrate the daily dose of brexpiprazole stepwise up to double the recommended dose over the course of 1 to 2 weeks.
Croatian: Ako se brekspiprazol primjenjuje istodobno s jakim induktorima CYP3A4 (npr. rifampicinom), u bolesnika stabiliziranog na brekspiprazolu potrebno je postepeno povisivati dnevnu dozu brekspiprazola do dvostruke preporučene doze tijekom 1 do 2 tjedna.
English: Elevations associated with brexpiprazole treatment are generally mild and may decline during administration, however, in some infrequent cases the effect may persist during administration (see section 4.8).
Croatian: Povišenje povezano s liječenjem brekspiprazolom općenito je blago i može opasti tijekom primjene; međutim, u nekim ne tako čestim slučajevima taj učinak može biti prisutan tijekom cijelog trajanja primjene (vidjeti dio 4.8).
English: As with other antipsychotics, brexpiprazole should be used with caution in patients who have a history of seizure disorder or other conditions that potentially lower the seizure threshold.
Croatian: Napadaji Kao i druge antipsihotike, brekspiprazol treba primjenjivati s oprezom u bolesnika koji u anamnezi imaju epileptički poremećaj ili druga stanja koja mogu sniziti konvulzivni prag.
English: Placebo Brexpiprazole (2 mg/day)* 113 96.55 Brexpiprazole (4 mg/day) Placebo Brexpiprazole (2 mg/day to 4 mg/day
Croatian: Placebo (2 mg na dan)* 113 96,55 Brekspiprazol (4 mg na dan) Placebo Brekspiprazol (2 mg na dan do 4 mg na dan)